Gene expression correlating with response to paclitaxel in ovarian carcinoma xenografts.

We have investigated gene expression profiles of human ovarian carcinomas in vivo during Taxol(R) (paclitaxel) treatment and observed a difference in expression. Nude mice bearing 1A9 or 1A9PTX22 xenografts were given 60 mg/kg of paclitaxel. Therapeutic efficacy was achieved for 1A9, while 1A9PTX22 did not respond. Tumor tissues harvested 4 and 24 h after treatment were evaluated by cDNA microarray against untreated tumors. Paclitaxel caused the modulation of more genes in 1A9 than in 1A9PTX22 tumors, in accordance to their therapeutic response. Most gene expression alterations were detected 24 h after paclitaxel administration and affected genes involved in various biological functions including cell cycle regulation and cell proliferation (CDC2, CDKN1A, PLAB, and TOP2A), apoptosis (BNIP3 and PIG8), signal transduction and transcriptional regulation (ARF1, ATF2, FOS, GNA11, HDAC3, MADH2, SLUG, and SPRY4), fatty acid biosynthesis and sterol metabolism (FDPS, IDI1, LIPA, and SC5D), and IFN-mediated signaling (G1P3, IFI16, IFI27, IFITM1, and ISG15). The modulation of two representative genes, CDKN1A and TOP2A, was validated by Northern analyses on a panel of seven ovarian carcinoma xenograft models undergoing treatment with paclitaxel. We found that the changes in expression level of these genes was strictly associated with the responsiveness to paclitaxel. Our study shows the feasibility of obtaining gene expression profiles of xenografted tumor models as a result of drug exposure. This in turn might provide insights related to the drugs' action in vivo that will anticipate the response to treatment manifested by tumors and could be the basis for novel approaches to molecular pharmacodynamics.

[1]  G. Church,et al.  Genomic sequencing. , 1993, Methods in molecular biology.

[2]  T. Fojo,et al.  Paclitaxel selects for mutant or pseudo-null p53 in drug resistance associated with tubulin mutations in human cancer , 2000, Oncogene.

[3]  G. Demers,et al.  Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis , 1996, Nature Medicine.

[4]  J. Mesirov,et al.  Chemosensitivity prediction by transcriptional profiling , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[5]  K. Du,et al.  Mitogenic Up-regulation of the PRL-1 Protein-tyrosine Phosphatase Gene by Egr-1 , 1999, The Journal of Biological Chemistry.

[6]  D. Beach,et al.  The cdc2 kinase is a nuclear protein that is essential for mitosis in mammalian cells , 1989, Cell.

[7]  B. Chabner,et al.  Discovery of differentially expressed genes associated with paclitaxel resistance using cDNA array technology: analysis of interleukin (IL) 6, IL-8, and monocyte chemotactic protein 1 in the paclitaxel-resistant phenotype. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[8]  F. Vikhanskaya,et al.  p73 overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis , 2001, Oncogene.

[9]  M. Kavallaris,et al.  Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. , 1997, The Journal of clinical investigation.

[10]  D. Botstein,et al.  A gene expression database for the molecular pharmacology of cancer , 2000, Nature Genetics.

[11]  Y. Nakatani,et al.  ATF-2 has intrinsic histone acetyltransferase activity which is modulated by phosphorylation , 2000, Nature.

[12]  S. Horwitz,et al.  Differential mitotic responses to microtubule-stabilizing and -destabilizing drugs. , 2002, Cancer research.

[13]  S. Vukicevic,et al.  Cloning and Characterization of a Novel Member of the Transforming Growth Factor-β/Bone Morphogenetic Protein Family* , 1998, The Journal of Biological Chemistry.

[14]  V. Ling.  P‐glycoprotein and resistance to anticancer drugs , 1992 .

[15]  Christos Sotiriou,et al.  Gene expression profiles of BRCA1-linked, BRCA2-linked, and sporadic ovarian cancers. , 2002, Journal of the National Cancer Institute.

[16]  B. Giovanella,et al.  Correlation between response to chemotherapy of human tumors in patients and in nude mice , 1983, Cancer.

[17]  G. Giaccone,et al.  p53 and chemosensitivity. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  Ash A. Alizadeh,et al.  Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling , 2000, Nature.

[19]  S. Elledge,et al.  The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases , 1993, Cell.

[20]  Christian A. Rees,et al.  Molecular portraits of human breast tumours , 2000, Nature.

[21]  H. Scher,et al.  The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  K. Jeang,et al.  Prevalent Loss of Mitotic Spindle Checkpoint in Adult T-cell Leukemia Confers Resistance to Microtubule Inhibitors* , 2002, The Journal of Biological Chemistry.

[23]  Matthew Freeman,et al.  Sprouty, an Intracellular Inhibitor of Ras Signaling , 1999, Cell.

[24]  T. Tsuruo,et al.  A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[25]  P. Allavena,et al.  Intraperitoneal and subcutaneous xenografts of human ovarian carcinoma in nude mice and their potential in experimental therapy , 1989, International journal of cancer.

[26]  Y. Ip,et al.  Human Slug Is a Repressor That Localizes to Sites of Active Transcription , 2000, Molecular and Cellular Biology.

[27]  K. Kinzler,et al.  A model for p53-induced apoptosis , 1997, Nature.

[28]  G. Riou,et al.  Over‐expression of MDR gene with no dna amplification in a multiple‐drug‐resistant human ovarian carcinoma cell line , 1989, International journal of cancer.

[29]  C. Davis,et al.  BIGEL analysis of gene expression in HL60 cells exposed to X rays or 60 Hz magnetic fields. , 1998, Radiation research.

[30]  M. D’Incalci,et al.  Ecteinascidin-743, a new marine natural product with potent antitumor activity on human ovarian carcinoma xenografts. , 1998, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  J. Lautenberger,et al.  Cellular genes analogous to retroviral onc genes are transcribed in human tumour cells , 1982, Nature.

[32]  Yusuke Nakamura,et al.  An integrated database of chemosensitivity to 55 anticancer drugs and gene expression profiles of 39 human cancer cell lines. , 2002, Cancer research.

[33]  J. Rothman,et al.  Stepwise assembly of functionally active transport vesicles , 1993, Cell.

[34]  B. Trask,et al.  Evolution of the mammalian G protein α subunit multigene family , 1992, Nature Genetics.

[35]  M. Broggini,et al.  Effect of Aplidin in acute lymphoblastic leukaemia cells , 2003, British Journal of Cancer.

[36]  A. Escargueil,et al.  Recruitment of cdc2 kinase by DNA topoisomerase II is coupled to chromatin remodeling , 2001, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[37]  F. Fitzpatrick,et al.  Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[38]  B. Sikic,et al.  Mechanisms of action of and resistance to antitubulin agents: microtubule dynamics, drug transport, and cell death. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  M. Christian,et al.  Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials , 2001, British Journal of Cancer.

[40]  T. Fojo,et al.  Molecular effects of paclitaxel: Myths and reality (a critical review) , 1999, International journal of cancer.

[41]  C. Bogdan,et al.  Taxol, a microtubule‐stabilizing antineoplastic agent, induces expression of tumor necrosis factor α and interleukin‐1 in macrophages , 1992, Journal of leukocyte biology.

[42]  T. Fojo,et al.  Paclitaxel-resistant Human Ovarian Cancer Cells Have Mutant β-Tubulins That Exhibit Impaired Paclitaxel-driven Polymerization* , 1997, The Journal of Biological Chemistry.

[43]  S. Gullans,et al.  Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells. , 1998, Biochemical and biophysical research communications.

[44]  M. Jordan,et al.  Microtubules and actin filaments: dynamic targets for cancer chemotherapy. , 1998, Current opinion in cell biology.

[45]  V. B. Pandey,et al.  An evaluation of toxicity of Taxus baccata Linn. (Talispatra) in experimental animals. , 2002, Journal of ethnopharmacology.

[46]  T. Fojo,et al.  Expression of beta-tubulin isotypes in human ovarian carcinoma xenografts and in a sub-panel of human cancer cell lines from the NCI-Anticancer Drug Screen: correlation with sensitivity to microtubule active agents. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  S. Mani,et al.  Validation of the pharmacodynamics of BMS-247550, an analogue of epothilone B, during a phase I clinical study. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[48]  B. Pollock.  Obstacles and opportunities for the use of health‐related quality‐of‐life assessment in pediatric cancer clinical trials (discussion) , 1999, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[49]  J. M. Boyd,et al.  Adenovirus E1B 19 kDa and Bcl-2 proteins interact with a common set of cellular proteins , 1994, Cell.

[50]  J. Moss,et al.  Molecules in the ARF Orbit* , 1998, The Journal of Biological Chemistry.

[51]  A. Iavarone,et al.  Id2 specifically alters regulation of the cell cycle by tumor suppressor proteins , 1996, Molecular and cellular biology.

[52]  J. da Silva,et al.  Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. , 1985, Cancer research.

[53]  W. Rose.  Taxol: a review of its preclinical in vivo antitumor activity. , 1992, Anti-cancer drugs.

[54]  Yusuke Nakamura,et al.  Genome-wide cDNA microarray screening to correlate gene expression profiles with sensitivity of 85 human cancer xenografts to anticancer drugs. , 2002, Cancer research.

[55]  M. Zucchetti,et al.  IDN5109, a taxane with oral bioavailability and potent antitumor activity. , 2000, Cancer research.

[56]  C. Turck,et al.  Mitotic Phosphorylation of the Dynein Light Intermediate Chain is Mediated by cdc2 Kinase , 2000, Traffic.

[57]  T. Pawson,et al.  A mammalian dual specificity protein kinase, Nek1, is related to the NIMA cell cycle regulator and highly expressed in meiotic germ cells. , 1992, The EMBO journal.

[58]  E. Scanziani,et al.  Antiangiogenic and antitumor activity of IDN 5390, a new taxane derivative. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[59]  J. Eberwine,et al.  Amplified RNA synthesized from limited quantities of heterogeneous cDNA. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[60]  R. Donehower,et al.  Drug therapy : paclitaxel (Taxol) , 1995 .